NCT02613598 is a Phase 1 clinical trial of Bortezomib in Hodgkin's Lymphoma, sponsored by University of Michigan Rogel Cancer Center.

Who is sponsoring NCT02613598?

NCT02613598 is sponsored by University of Michigan Rogel Cancer Center.

What drugs are being tested in NCT02613598?

Interventions in NCT02613598: Bortezomib, Ruxolitinib.

What condition does NCT02613598 study?

NCT02613598 studies Hodgkin's Lymphoma, Lymphoma, Non-Hodgkin.

Is NCT02613598 still recruiting?

NCT02613598 is currently completed. Last updated 20 December 2021.

Last reviewed 2021-12-20 · How we verify

NCT02613598

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma

Completed Phase 1 Last updated 20 December 2021

What this trial tests

Phase 1 trial testing Bortezomib in Hodgkin's Lymphoma in 15 participants. Completed in 7 June 2021.

Timeline

12 May 2016

Primary endpoint
7 June 2021

7 June 2021

Quick facts

Lead sponsor	University of Michigan Rogel Cancer Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	12 May 2016
Primary completion	7 June 2021
Estimated completion	7 June 2021
Sites	1 location across United States

Drugs / interventions tested

Bortezomib (bortezomib) — full drug profile →
Ruxolitinib (RUXOLITINIB) — full drug profile →

Conditions studied

Hodgkin's Lymphoma — all drugs for Hodgkin's Lymphoma →
Lymphoma, Non-Hodgkin — all drugs for Lymphoma, Non-Hodgkin →

Sponsor

University of Michigan Rogel Cancer Center

Who can join

18 and older, any sex, with Hodgkin's Lymphoma or Lymphoma, Non-Hodgkin. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this research study is to determine the maximum tolerated dose (MTD) of Ruxolitinib (Jakafi) in combination with standard dose Bortezomib (Velcade) in patients with relapsed or refractory Hodgkin (HL) and Non-Hodgkin Lymphoma (NHL).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition.
Luo Y, Alexander M, Gadina M, O'Shea JJ, et al · · 2021 · cited 92× · PMID 34625141 · DOI 10.1016/j.jaci.2021.08.004
Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity.
Begalli F, Bennett J, Capece D, Verzella D, et al · · 2017 · cited 51× · PMID 28829404 · DOI 10.3390/biomedicines5030050
The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target.
Verzella D, Cornice J, Arboretto P, Vecchiotti D, et al · · 2022 · cited 23× · PMID 36140335 · DOI 10.3390/biomedicines10092233
Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?
Klein K, Stoiber D, Sexl V, Witalisz-Siepracka A. · · 2021 · cited 22× · PMID 34073410 · DOI 10.3390/cancers13112611
Advancements in B-Cell Non-Hodgkin's Lymphoma: From Signaling Pathways to Targeted Therapies.
Alfaifi A, Bahashwan S, Alsaadi M, Ageel AH, et al · · 2024 · cited 5× · PMID 39563886 · DOI 10.1155/2024/5948170
Current advances in Hodgkin's lymphoma.
Vadakara J, Andrick B. · · 2019 · cited 4× · PMID 30993260 · DOI 10.1016/j.cdtm.2019.02.003
Incorporation of Ruxolitinib in the Management of Refractory/Relapsed Hodgkin Lymphoma: Where Do We Stand?
Al Sharie AH, Abu Mousa BM, Alomari AO. · · 2023 · PMID 37752987 · DOI 10.46989/001c.87501
Cytoskeleton Dynamics in Peripheral T Cell Lymphomas: An Intricate Network Sustaining Lymphomagenesis.
Fragliasso V, Tameni A, Inghirami G, Mularoni V, et al · · 2021 · PMID 33928032 · DOI 10.3389/fonc.2021.643620

Verify or expand the search:

Other trials of Bortezomib

Trials testing the same drug.

NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT07428369 — A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · Phase 2, PHASE3 · not yet recruiting
NCT07224672 — A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, an · Phase 2 · not yet recruiting
NCT07391657 — A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regi · Phase 3 · recruiting

Other recruiting trials for Hodgkin's Lymphoma

Currently open trials in the same condition.

NCT05355051 — A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma · Phase 2 · recruiting

Other University of Michigan Rogel Cancer Center trials

Trials by the same sponsor.

NCT06914479 — Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and · Phase 1 · recruiting
NCT07481344 — SunBeast: Evaluating UV Protective Behaviors and Education Interventions Among Ultrarunners · NA · not yet recruiting
NCT07526545 — Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial · NA · not yet recruiting
NCT07443943 — A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive · Phase 2 · recruiting
NCT07365007 — A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Ca · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02613598 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Michigan Rogel Cancer Center
Last refreshed: 20 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02613598.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing